Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care

Abstract Objective: To assess clinical inertia, defined as failure to intensify antidiabetic treatment of patients who have not achieved the HbA1c therapeutic goal ( 7%). Research design and methods: Multicenter cross-sectional study. Clinical inertia was assessed in a random sample of type 2 diabet...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2013-11, Vol.29 (11), p.1495-1502
Main Authors: Mata-Cases, Manel, Benito-Badorrey, Belén, Roura-Olmeda, Pilar, Franch-Nadal, Josep, Pepió-Vilaubí, Josep Maria, Saez, Marc, Coll-de-Tuero, Gabriel
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Blood Glucose
Clinical inertia
Cross-Sectional Studies
Diabetes Mellitus, Type 2 - drug therapy
Diabetes. Impaired glucose tolerance
Drug Therapy, Combination
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Glycated Hemoglobin A - analysis
Glycated Hemoglobin A - metabolism
Glycemic control
Humans
Hyperglycemia - drug therapy
Hypoglycemic Agents - therapeutic use
Insulin - therapeutic use
Male
Medical sciences
Pharmacology. Drug treatments
Physicians, Primary Care
Practice Patterns, Physicians
Primary care
Primary Health Care
Retrospective Studies
Spain
Treatment intensification
Treatment Outcome
Type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective: To assess clinical inertia, defined as failure to intensify antidiabetic treatment of patients who have not achieved the HbA1c therapeutic goal ( 7%). Research design and methods: Multicenter cross-sectional study. Clinical inertia was assessed in a random sample of type 2 diabetes mellitus (T2DM) patients seen in primary care centers. Results: A total of 2783 patients (51.3% males; mean age: 68 [±11.5] years; diabetes duration: 7.1 [±5.6] years; mean HbA1c: 6.8 [±1.5]) were analyzed. Of those, 997 (35.8%) had HbA1c >7%. Treatment was intensified in 66.8% and consisted of: dose increase (40.5%); addition of oral antidiabetic (45.8%); or insulin treatment initiation (3.7%). Mean HbA1c values in patients for whom treatment was intensified vs. non-intensified were 8.4% (±1.2) vs. 8.2% (±1.2), p 
ISSN:0300-7995
1473-4877
DOI:10.1185/03007995.2013.833089